Products 4CMenB
4CMenB Approved Completed 🔥 Hot Jul 21, 2014 → Apr 27, 2018
About 4CMenB 4CMenB is a approved stage product being developed by Novartis for Meningitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02080559. Target conditions include Meningitis.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT02080559 Approved Completed Jul 21, 2014 Apr 27, 2018 Meningitis
Product Company Stage Hype Score RotaTeq® + NeisVac-C® Merck Phase 3 Daptomycin Merck Pre-clinical Meningococcal ACWY conjugate vaccine Novartis Phase 3 Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine Novartis Approved Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaP Novartis Phase 3 Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and Menveo Novartis Phase 3 Meningococcal ACWY conjugate vaccine Novartis Phase 3 MenACWY-CRM + MenC-CRM + DTaP-Hib-IPV + PC7 + MMR + Varicella Novartis Phase 2 Hib-CRM197 + Hib-TT Novartis Phase 3 Novartis Meningococcal ACWY Conjugate Vaccine + Tdap Vaccine + Novartis Meningococcal ACWY Conjugate Vaccine Novartis Phase 3 MenACWY-CRM conjugate vaccine, adjuvanted + MenACWY polysaccharide vaccine + MenACWY-CRM conjugate vaccine, unadjuvanted Novartis Phase 2 meningococcal B vaccine & meningococcal ACYW conjugate vaccine Novartis Phase 2 Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine Novartis Phase 2 Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine Novartis Phase 3 Meningococcal (group B) multicomponent recombinant adsorbed vaccine Novartis Phase 3 MenACWY-CRM197 (two doses) + MenC + PCV7 + DTPa-IPV-HepB-Hib + MenACWY-CRM197 (one dose) Novartis Phase 3 MenACWY-CRM197 + DTaP (Diptheria, Tetanus, Pertussis) Vaccine + Hib (Haemophilus influenza b) Vaccine + IPV (Inactivated Polio Vaccine) Vaccine + Pneumococcal conjugate Vaccine + MMR (Measles, Mumps, and Rubella) Vaccine + Varicella Vaccine + Hepatitis A Virus Novartis Phase 3 Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years) Novartis Phase 3 Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Control + Meningococcal B vaccine with antipyretic Novartis Phase 2 Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1) + Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2) + Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3) + Infanrix Hexa + Menjugate + Prevenar Novartis Phase 3
Other Products from Novartis